MannKind | MNKD - Ebitda


MannKind reported $2.93M in EBITDA for its fiscal quarter ending in March of 2026.





Ebitda Change Date
Adma Biologics USD 61.07M 12.52M Mar/2026
BioCryst Pharmaceuticals USD 51.7M 30.14M Sep/2025
Eli Lilly USD 10.29B 1.86B Mar/2026
Halozyme Therapeutics USD 328.81M 109.24M Jun/2026
Insmed USD -148.3M 165.88M Mar/2026
Karyopharm Therapeutics USD -26.2M 1.83M Sep/2024
MacroGenics USD -30.2M 52.15M Mar/2026
MannKind USD 2.93M 5.98M Mar/2026
Merck USD -1.54B 7.84B Mar/2026
Minerva Neurosciences USD -4.36M 1.71M Sep/2024
Novavax USD 19.36M 190.79M Dec/2025
Novo Nordisk DKK 37.36B 31.84B Jun/2026
Pfizer USD 6.01B 18M Jun/2026
Sanofi EUR 3.69B 375M Jun/2026
Xencor USD -34.63M 86.74M Jun/2026